Analysts at HC Wainwright assumed coverage on shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) in a research report issued to clients and investors on Thursday. The brokerage set a “buy” rating and a $12.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 100.00% from the company’s current price.

MRTX has been the topic of several other research reports. Zacks Investment Research raised Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a report on Wednesday, November 9th. Piper Jaffray Cos. set a $7.00 price objective on Mirati Therapeutics and gave the stock a “hold” rating in a report on Thursday, August 18th. Wedbush reaffirmed an “outperform” rating and set a $12.00 price objective on shares of Mirati Therapeutics in a report on Friday, November 4th. Finally, Leerink Swann reaffirmed a “hold” rating and set a $7.00 price objective on shares of Mirati Therapeutics in a report on Friday, November 11th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Mirati Therapeutics has an average rating of “Buy” and an average price target of $16.25.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ:MRTX) opened at 6.00 on Thursday. Mirati Therapeutics has a one year low of $4.40 and a one year high of $39.16. The stock’s market cap is $119.54 million. The stock’s 50 day moving average price is $5.49 and its 200-day moving average price is $7.52.

A number of hedge funds have recently modified their holdings of the company. Aviva Holdings Ltd. increased its stake in shares of Mirati Therapeutics by 28.9% in the second quarter. Aviva Holdings Ltd. now owns 1,992,085 shares of the company’s stock valued at $10,877,000 after buying an additional 446,084 shares during the last quarter. Citadel Advisors LLC increased its stake in shares of Mirati Therapeutics by 72.3% in the second quarter. Citadel Advisors LLC now owns 22,064 shares of the company’s stock valued at $120,000 after buying an additional 9,258 shares during the last quarter. KCG Holdings Inc. acquired a new stake in shares of Mirati Therapeutics during the second quarter valued at approximately $102,000. Alliancebernstein L.P. acquired a new stake in shares of Mirati Therapeutics during the second quarter valued at approximately $125,000. Finally, Trexquant Investment LP acquired a new stake in shares of Mirati Therapeutics during the second quarter valued at approximately $263,000. 69.49% of the stock is currently owned by institutional investors and hedge funds.

5 Day Chart for NASDAQ:MRTX

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.